• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

19.25 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 243
Open 19.25
Bid (Size) 18.81 (100)
Ask (Size) 19.60 (300)
Prev. Close 19.25
Today's Range 19.25 - 19.25
52wk Range 4.610 - 24.27
Shares Outstanding 96,008,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
July 07, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
June 26, 2026
From Avalo Therapeutics
Via GlobeNewswire

Performance

YTD
+13.1%
+13.1%
1 Month
+51.1%
+51.1%
3 Month
+20.9%
+20.9%
6 Month
+21.0%
+21.0%
1 Year
+305.3%
+305.3%

More News

Read More
News headline image
Avalo Therapeutics Appoints Ron Philip to Board of Directors
June 23, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
June 16, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 13, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results ↗
May 06, 2026
Via Benzinga
Wednesday's session: gap up and gap down stocks ↗
May 06, 2026
Via Chartmill
These stocks are moving in today's pre-market session ↗
May 06, 2026
Via Chartmill
News headline image
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
May 05, 2026
From Avalo Therapeutics
Via GlobeNewswire
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
May 05, 2026
Via Chartmill
News headline image
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 05, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
May 05, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Purchases Optional Milestone Buyout
April 28, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
March 23, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
February 04, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
November 06, 2025
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
November 03, 2025
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 29, 2025
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug ↗
October 22, 2025
Via Stocktwits
News headline image
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
October 01, 2025
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Wondering what's happening in today's pre-market session? ↗
September 29, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
September 29, 2025
Via Benzinga

Frequently Asked Questions

Is Avalo Therapeutics, Inc. - Common Stock publicly traded?
Yes, Avalo Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Avalo Therapeutics, Inc. - Common Stock trade on?
Avalo Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Avalo Therapeutics, Inc. - Common Stock?
The ticker symbol for Avalo Therapeutics, Inc. - Common Stock is AVTX on the Nasdaq Stock Market
What is the current price of Avalo Therapeutics, Inc. - Common Stock?
The current price of Avalo Therapeutics, Inc. - Common Stock is 19.25
When was Avalo Therapeutics, Inc. - Common Stock last traded?
The last trade of Avalo Therapeutics, Inc. - Common Stock was at 07/07/26 04:00 PM ET
What is the market capitalization of Avalo Therapeutics, Inc. - Common Stock?
The market capitalization of Avalo Therapeutics, Inc. - Common Stock is 1.85B
How many shares of Avalo Therapeutics, Inc. - Common Stock are outstanding?
Avalo Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap